Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Operating Cash Flow

Cash generated by the company's core business operations during the period.

Puma Biotechnology, Inc.NASDAQ: PBYI

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow growth accelerates

Q1 FY2026 operating cash flow of $15.42M rose 326.8% year over year, ahead of the +71.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 6.9% from the prior quarter.

Context

  • Operating cash flow amounted to 18.3% of revenue in FY2025, up 1.4 pp from a year earlier.
  • Operating cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +326.8% holds above the trailing-twelve-month pace of +71.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.42M+6.9% QoQ
Last fiscal yearDec 2025
$41.8M+7.4% YoY
LTMMar 2026
$53.61M+71.4% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+326.8%——
1 year+7.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
41.8M USD
Year-over-year change
+7.4%
4-year CAGR
+19.3%

Operating Cash Flow vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +71.4% is the highest of 10, against a peer median of +0.5%.
  • Operating cash flow amounts to 23.6% of revenue for PBYI, versus a peer median of 176.5%.
PBYI Competitors
Operating Cash Flow for PBYI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VSTMVerastem, Inc.LTM Mar 2026$150.95M USD+31.1%+29.3%304.4%
TNGXTango Therapeutics, Inc.LTM Sep 2026$150.09M USD+2.9%+8.4%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$134.47M USD+12.4%+54.4%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$110.88M USD-3.8%+14.7%—
NUVBNuvation Bio Inc.LTM Jun 2026$82.62M USD-50.9%+21.7%48.6%
MGNXMacroGenics, Inc.LTM Mar 2026$69.96M USD+0.5%-2.3%44.5%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$53.61M USD+71.4%—23.6%
CRDFCardiff Oncology, Inc.LTM Mar 2026$37.42M USD-12.5%+3.9%7127.0%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$34.03M USD-376.5%——
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$30.89M CAD+18.8%+5.7%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥13.15M CNY—-73.5%—
Peer median (excluding PBYI) —+0.5%+8.4%176.5%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29.13M)2K21.59M30.28M31.11M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
Deferred Income Tax000(7.08M)3.25M
Stock-Based Compensation32.63M11.83M10.25M8.25M6.94M
Change in Working Capital(1.31M)(44.5M)(17.85M)(3.54M)(10.08M)
Accounts Receivables(5.98M)(7.82M)(8.37M)16.35M(21.28M)
Inventory(3.66M)2.58M(2.55M)(1.64M)3.21M
Accounts Payables(902K)(4.73M)449K(1.38M)(453K)
Other Working Capital9.23M(34.52M)(7.38M)(16.86M)8.45M
Other Non-Cash Items7.15M7M1.51M(519K)(358K)
Operating Cash Flow20.65M(15.83M)27.01M38.92M41.8M
Capital Expenditures0(7M)(12.64M)(56K)(71K)
Acquisitions (Net)00000
Purchases of Investments(38.07M)(4.84M)(23.81M)(76.23M)(108.14M)
Sales of Investments27.19M18.94M17.33M55.85M72.02M
Other Investing Activities00(12.5M)00
Investing Cash Flow(10.88M)7.1M(19.13M)(20.44M)(36.19M)
Debt Repayment(1.5M)00(33.33M)(44.44M)
Common Stock Issued012.5M0150K130K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(30.43M)(277K)0(666K)(888K)
Financing Cash Flow(31.93M)12.22M0(33.85M)(45.2M)
Effect of Forex Changes00000
Net Change in Cash(22.16M)3.5M7.88M(15.37M)(39.58M)
Free Cash Flow20.65M(22.83M)14.37M38.86M41.73M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.